دورية أكاديمية
Silexan in anxiety disorders: Clinical data and pharmacological background.
| العنوان: | Silexan in anxiety disorders: Clinical data and pharmacological background. |
|---|---|
| المؤلفون: | Kasper S; a Department of Psychiatry and Psychotherapy , Medical University of Vienna , Vienna , Austria., Müller WE; b Department of Pharmacology Biocenter , Goethe-University , Frankfurt , Germany., Volz HP; c Psychotherapy and Psychosomatic Medicine , Hospital for Psychiatry , Werneck , Germany., Möller HJ; d Clinic for Psychiatry and Psychotherapy , Ludwig Maximilians University , Munich , Germany., Koch E; e Research and Development Department, Dr. Willmar-Schwabe GmbH & Co. KG , Karlsruhe , Germany., Dienel A; e Research and Development Department, Dr. Willmar-Schwabe GmbH & Co. KG , Karlsruhe , Germany. |
| المصدر: | The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry [World J Biol Psychiatry] 2018 Sep; Vol. 19 (6), pp. 412-420. Date of Electronic Publication: 2017 Jun 19. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Informa Healthcare Country of Publication: England NLM ID: 101120023 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1814-1412 (Electronic) Linking ISSN: 15622975 NLM ISO Abbreviation: World J Biol Psychiatry Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: London : Informa Healthcare Original Publication: Glasgow : WFSBP, 2000- |
| مواضيع طبية MeSH: | Anti-Anxiety Agents/*pharmacology , Anxiety Disorders/*drug therapy , Oils, Volatile/*pharmacology , Phytotherapy/*methods , Plant Oils/*pharmacology, Anti-Anxiety Agents/administration & dosage ; Anti-Anxiety Agents/adverse effects ; Humans ; Lavandula ; Oils, Volatile/administration & dosage ; Oils, Volatile/adverse effects ; Plant Oils/administration & dosage ; Plant Oils/adverse effects |
| مستخلص: | Objectives: Silexan is a lavender oil preparation available in 80-mg capsules. Here we review clinical trials investigating its anxiolytic efficacy, safety and tolerability in humans, as well as preclinical investigations supporting this therapeutic use. Methods: Besides three selected publications reporting preclinical investigations, seven clinical trials are included, of which five had a treatment duration of 6 or 10 weeks. Primary outcome measure was the HAM-A total score reduction, while single items were assessed with regard to effects on concomitant depressive symptoms and on quality of sleep. Results: In patients with subthreshold (subsyndromal) anxiety or generalised anxiety disorder (GAD), an anxiolytic effect of Silexan was evident after 2 weeks. HAM-A total score reductions between baseline and end of treatment were significantly superior to placebo in patients with subthreshold anxiety and comparable with those achieved under lorazepam or paroxetine in patients with GAD. In addition, Silexan had beneficial effects on typical concomitant symptoms of anxiety disorders, such as impaired sleep, somatic complaints, co-morbid depression or decreased quality of life. Except for mild gastrointestinal symptoms, Silexan did not induce any adverse effects and did not cause drug interactions, sedation or withdrawal symptoms at daily doses of 80 or 160 mg. Conclusions: Silexan is a safe and effective treatment in anxiety disorders. |
| فهرسة مساهمة: | Keywords: Silexan; anxiety disorder; clinical trial; lavender oil; pharmacology |
| المشرفين على المادة: | 0 (Anti-Anxiety Agents) 0 (Oils, Volatile) 0 (Plant Oils) ZBP1YXW0H8 (lavender oil) |
| تواريخ الأحداث: | Date Created: 20170518 Date Completed: 20181105 Latest Revision: 20211204 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1080/15622975.2017.1331046 |
| PMID: | 28511598 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1814-1412 |
|---|---|
| DOI: | 10.1080/15622975.2017.1331046 |